New drug XB628 aims to boost Body's natural killers against tough cancers

NCT ID NCT06952010

First seen Nov 01, 2025 · Last updated May 04, 2026 · Updated 31 times

Summary

This early-phase trial tests a new drug called XB628 in about 75 people whose advanced solid tumors have not responded to standard treatments. XB628 is designed to help the body's natural killer cells attack cancer cells more effectively. The main goals are to check safety and find the right dose.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Exelixis Clinical Site #1

    RECRUITING

    Hickory, North Carolina, 28602, United States

  • Exelixis Clinical Site #10

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • Exelixis Clinical Site #2

    RECRUITING

    San Antonio, Texas, 78229, United States

  • Exelixis Clinical Site #3

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Exelixis Clinical Site #8

    RECRUITING

    Tampa, Florida, 33612, United States

  • Exelixis Clinical Site #9

    RECRUITING

    Houston, Texas, 77030, United States

  • Exelixis Site #4

    RECRUITING

    New Haven, Connecticut, 06520, United States

  • Exelixis Site #5

    RECRUITING

    San Francisco, California, 94158, United States

  • Exelixis Site #6

    RECRUITING

    St Louis, Missouri, 63108, United States

  • Exelixis Site #7

    RECRUITING

    New York, New York, 10029, United States

Conditions

Explore the condition pages connected to this study.